Mucinous cystadenocarcinoma medical therapy

Revision as of 18:45, 19 April 2019 by Qurrat-ul-ain Abid (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mucinous cystadenocarcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Mucinous Cystadenocarcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mucinous cystadenocarcinoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mucinous cystadenocarcinoma medical therapy

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mucinous cystadenocarcinoma medical therapy

CDC on Mucinous cystadenocarcinoma medical therapy

Mucinous cystadenocarcinoma medical therapy in the news

Blogs on Mucinous cystadenocarcinoma medical therapy

Directions to Hospitals Treating Mucinous cystadenocarcinoma

Risk calculators and risk factors for Mucinous cystadenocarcinoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2], Ammu Susheela, M.D. [3]

Overview

The main mode of treatment of mucinous cystadenocarcinoma is chemotherapy and radiation.

Medical Therapy

Reference

  1. Ovary Epithelial tumors. Atlasgeneticsoncology (2016).http://atlasgeneticsoncology.org/Tumors/OvaryEpithTumID5230.html Accessed on February 29, 2016
  2. McMillan MT, Lewis RS, Drebin JA, Teitelbaum UR, Lee MK, Roses RE, Fraker DL, Vollmer CM (February 2016). "The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN)". Cancer. 122 (4): 521–33. doi:10.1002/cncr.29803. PMID 26587698.


Template:WikiDoc Sources